Which has stronger earnings and valuation, CYTK or BIIB?

Biogen has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytokinetics $67.67M 135.65 -$784.96M -$7.22 N/A Biogen $9.89B 3.24 $1.29B $5.65 38.43

Is CYTK or BIIB more profitable?

Biogen has a net margin of 8.32% compared to Cytokinetics' net margin of -1,321.12%. Biogen's return on equity of 11.18% beat Cytokinetics' return on equity. Company Net Margins Return on Equity Return on Assets Cytokinetics -1,321.12% N/A -51.01% Biogen 8.32% 11.18% 6.88%

Does the media prefer CYTK or BIIB?

In the previous week, Biogen had 3 more articles in the media than Cytokinetics. MarketBeat recorded 12 mentions for Biogen and 9 mentions for Cytokinetics. Biogen's average media sentiment score of 1.10 beat Cytokinetics' score of 0.90 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALNY or CYTK?

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Cytokinetics. MarketBeat recorded 14 mentions for Alnylam Pharmaceuticals and 9 mentions for Cytokinetics. Alnylam Pharmaceuticals' average media sentiment score of 1.12 beat Cytokinetics' score of 0.90 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 8 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is INSM or CYTK more profitable?

Insmed has a net margin of -76.94% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% Cytokinetics -1,321.12% N/A -51.01%

Does the media prefer INSM or CYTK?

In the previous week, Insmed had 2 more articles in the media than Cytokinetics. MarketBeat recorded 11 mentions for Insmed and 9 mentions for Cytokinetics. Insmed's average media sentiment score of 1.15 beat Cytokinetics' score of 0.90 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BNTX or CYTK more profitable?

BioNTech has a net margin of -63.54% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -63.54% -6.86% -6.00% Cytokinetics -1,321.12% N/A -51.01%

Does the media favor BNTX or CYTK?

In the previous week, BioNTech had 12 more articles in the media than Cytokinetics. MarketBeat recorded 21 mentions for BioNTech and 9 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.90 beat BioNTech's score of 0.44 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cytokinetics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, INCY or CYTK?

Incyte has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.82B 4.23 $1.29B $7.85 15.47 Cytokinetics $67.67M 135.65 -$784.96M -$7.22 N/A

Is INCY or CYTK more profitable?

Incyte has a net margin of 27.71% compared to Cytokinetics' net margin of -1,321.12%. Incyte's return on equity of 29.93% beat Cytokinetics' return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% Cytokinetics -1,321.12% N/A -51.01%

Does the media favor INCY or CYTK?

In the previous week, Incyte had 10 more articles in the media than Cytokinetics. MarketBeat recorded 19 mentions for Incyte and 9 mentions for Cytokinetics. Incyte's average media sentiment score of 0.98 beat Cytokinetics' score of 0.90 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 9 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cytokinetics (CYTK) Competitors

$73.77 +0.15 (+0.20%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$73.76 -0.01 (-0.01%)

As of 09/11/2026 07:30 PM Eastern

Compare

CYTK vs. BIIB, ALNY, INSM, BNTX, and INCY

Should you buy Cytokinetics stock or one of its competitors? Cytokinetics's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Insmed (INSM), BioNTech (BNTX), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cytokinetics compare to Biogen?

Cytokinetics (NASDAQ:CYTK) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Cytokinetics presently has a consensus price target of $103.37, suggesting a potential upside of 40.12%. Biogen has a consensus price target of $230.14, suggesting a potential upside of 5.98%. Given Cytokinetics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cytokinetics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Biogen has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$67.67M	135.65	-$784.96M	-$7.22	N/A
Biogen	$9.89B	3.24	$1.29B	$5.65	38.43

Cytokinetics has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market.

Biogen has a net margin of 8.32% compared to Cytokinetics' net margin of -1,321.12%. Biogen's return on equity of 11.18% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
Biogen	8.32%	11.18%	6.88%

87.9% of Biogen shares are held by institutional investors. 2.6% of Cytokinetics shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Biogen had 3 more articles in the media than Cytokinetics. MarketBeat recorded 12 mentions for Biogen and 9 mentions for Cytokinetics. Biogen's average media sentiment score of 1.10 beat Cytokinetics' score of 0.90 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Biogen beats Cytokinetics on 11 of the 16 factors compared between the two stocks.

How does Cytokinetics compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Alnylam Pharmaceuticals has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.96	$313.75M	$5.38	46.22
Cytokinetics	$67.67M	135.65	-$784.96M	-$7.22	N/A

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Cytokinetics' net margin of -1,321.12%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Cytokinetics	-1,321.12%	N/A	-51.01%

Alnylam Pharmaceuticals presently has a consensus target price of $376.67, indicating a potential upside of 51.47%. Cytokinetics has a consensus target price of $103.37, indicating a potential upside of 40.12%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Alnylam Pharmaceuticals is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Cytokinetics. MarketBeat recorded 14 mentions for Alnylam Pharmaceuticals and 9 mentions for Cytokinetics. Alnylam Pharmaceuticals' average media sentiment score of 1.12 beat Cytokinetics' score of 0.90 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats Cytokinetics on 13 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to Insmed?

Insmed (NASDAQ:INSM) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Insmed currently has a consensus price target of $205.52, indicating a potential upside of 58.81%. Cytokinetics has a consensus price target of $103.37, indicating a potential upside of 40.12%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85

Insmed has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

Cytokinetics has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$1.14B	24.84	-$1.28B	-$4.11	N/A
Cytokinetics	$67.67M	135.65	-$784.96M	-$7.22	N/A

Insmed has a net margin of -76.94% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Cytokinetics	-1,321.12%	N/A	-51.01%

In the previous week, Insmed had 2 more articles in the media than Cytokinetics. MarketBeat recorded 11 mentions for Insmed and 9 mentions for Cytokinetics. Insmed's average media sentiment score of 1.15 beat Cytokinetics' score of 0.90 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Insmed beats Cytokinetics on 11 of the 15 factors compared between the two stocks.

How does Cytokinetics compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Cytokinetics has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.65B	9.23	-$1.29B	-$7.83	N/A
Cytokinetics	$67.67M	135.65	-$784.96M	-$7.22	N/A

BioNTech has a net margin of -63.54% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Cytokinetics	-1,321.12%	N/A	-51.01%

BioNTech has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

In the previous week, BioNTech had 12 more articles in the media than Cytokinetics. MarketBeat recorded 21 mentions for BioNTech and 9 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.90 beat BioNTech's score of 0.44 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytokinetics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech presently has a consensus target price of $126.00, indicating a potential upside of 30.26%. Cytokinetics has a consensus target price of $103.37, indicating a potential upside of 40.12%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts clearly believe Cytokinetics is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85

15.5% of BioNTech shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 2.6% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Cytokinetics beats BioNTech on 9 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to Incyte?

Incyte (NASDAQ:INCY) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

Incyte presently has a consensus price target of $124.05, suggesting a potential upside of 2.12%. Cytokinetics has a consensus price target of $103.37, suggesting a potential upside of 40.12%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts clearly believe Cytokinetics is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85

Incyte has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market.

Incyte has a net margin of 27.71% compared to Cytokinetics' net margin of -1,321.12%. Incyte's return on equity of 29.93% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Cytokinetics	-1,321.12%	N/A	-51.01%

In the previous week, Incyte had 10 more articles in the media than Cytokinetics. MarketBeat recorded 19 mentions for Incyte and 9 mentions for Cytokinetics. Incyte's average media sentiment score of 0.98 beat Cytokinetics' score of 0.90 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	9 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.82B	4.23	$1.29B	$7.85	15.47
Cytokinetics	$67.67M	135.65	-$784.96M	-$7.22	N/A

97.0% of Incyte shares are held by institutional investors. 16.2% of Incyte shares are held by insiders. Comparatively, 2.6% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Incyte beats Cytokinetics on 13 of the 17 factors compared between the two stocks.

Get Cytokinetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYTK vs. The Competition

Export

Metric	Cytokinetics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.16B	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-10.22	14.25	275.24	25.29
Price / Sales	135.65	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	-13.69	15.12	10.33	6.20
Net Income	-$784.96M	-$22.86M	$3.50B	$358.50M
7 Day Performance	1.44%	-4.34%	-3.32%	-2.35%
1 Month Performance	-2.47%	-0.02%	-0.41%	-2.77%
1 Year Performance	44.28%	40.64%	19.21%	7.63%

Cytokinetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYTK Cytokinetics	2.7439 of 5 stars	$73.77 +0.2%	$103.37 +40.1%	+38.4%	$9.16B	$67.67M	N/A	673	Analyst Forecast Insider Trade
BIIB Biogen	3.2665 of 5 stars	$216.65 -0.8%	$227.79 +5.1%	+45.9%	$32.28B	$10.03B	38.35	7,500	Positive News Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.4558 of 5 stars	$240.69 +1.5%	$386.14 +60.4%	-46.9%	$31.73B	$4.80B	44.74	2,770	Positive News Analyst Forecast
INSM Insmed	3.4197 of 5 stars	$121.82 +2.8%	$205.52 +68.7%	-11.2%	$25.89B	$606.42M	N/A	1,664	News Coverage Insider Trade
BNTX BioNTech	4.2611 of 5 stars	$101.61 -0.5%	$127.44 +25.4%	-7.3%	$25.81B	$3.25B	N/A	7,807	Analyst Downgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYTK) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytokinetics (CYTK) Competitors